ImmuCell to Announce Preliminary Financial Results for the Year Ended December 31, 2019
February 13 2020 - 9:17AM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically-proven and
practical products that improve the health and productivity of
dairy and beef cattle, will report unaudited financial results for
the year ended December 31, 2019 after the market closes on
Tuesday, February 18, 2020.
The Company has scheduled a conference call on Wednesday,
February 19, 2020 at 9:00 AM ET to review the 2019 results.
Interested parties can access the conference call by dialing (844)
855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM
ET on Wednesday, February 19, 2020. A teleconference replay of the
call will be available for seven days at (877) 344-7529 (toll free)
or (412) 317-0088 (international), utilizing confirmation
#10138781.
Investors are encouraged to review the Company’s updated
Corporate Presentation slide deck that provides an overview of the
Company’s business and is available under the “Investors” tab of
the Company’s website at www.immucell.com, or by request to the
Company. The Company expects to file its Annual Report on Form 10-K
on or about March 27, 2020.
About ImmuCell: ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create
scientifically-proven and practical products that improve the
health and productivity of dairy and beef cattle. ImmuCell
markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
livestock, and is in the late stages of developing
Re-Tain™, a novel treatment for mastitis without a
milk discard requirement that provides an alternative to
traditional antibiotics. Press releases and other information
about the Company are available at: http://www.immucell.com.
Contact:
Michael F. Brigham, President and CEOImmuCell Corporation(207)
878-2770
Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLC(602)
889-9700iccc@lythampartners.com
Cautionary Note Regarding Forward-Looking Statements
(Safe Harbor Statement):
This Press Release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to: our
plans and strategies for our business; projections of future
financial or operational performance; the timing and outcome of
pending or anticipated applications for regulatory approvals;
factors that may affect the dairy and beef industries and future
demand for our products; the scope and timing of ongoing and future
product development work and commercialization of our products;
future costs of product development efforts; the estimated
prevalence rate of subclinical mastitis; the expected efficacy of
new products; estimates about the market size for our products;
future market share of and revenue generated by current products
and products still in development; our ability to increase
production output and reduce costs of goods sold associated with
our new product, Tri-Shield First
Defense®; the future adequacy of our own manufacturing
facilities or those of third parties with which we have contractual
relationships to meet demand for our products on a timely basis;
the anticipated costs of (or time to complete) planned expansions
of our manufacturing facilities and the adequacy of our funds
available for these projects; the continuing availability to us on
reasonable terms of third-party providers of critical products or
services; the robustness of our manufacturing processes and related
technical issues; estimates about our production capacity,
efficiency and yield; the future adequacy of our working capital
and the availability and cost of third-party financing; future
regulatory requirements relating to our products; future expense
ratios and margins; future compliance with bank debt covenants;
future cost of our variable interest rate exposure on most of our
bank debt; costs associated with sustaining compliance with current
Good Manufacturing Practice (cGMP) regulations in our current
operations and attaining such compliance for the facility to
produce the Nisin Drug Substance; implementation of international
trade tariffs that could reduce the export of dairy products, which
could in turn weaken the price received by our customers for their
products; our effectiveness in competing against competitors within
both our existing and our anticipated product markets; the
cost-effectiveness of additional sales and marketing expenditures
and resources; anticipated changes in our manufacturing
capabilities and efficiencies; the value of our net deferred tax
assets; projections about depreciation expense and its impact on
income for book and tax return purposes; anticipated market
conditions; and any other statements that are not historical facts.
Forward-looking statements can be identified by the use of words
such as “expects”, “may”, “anticipates”, “aims”, “intends”,
“would”, “could”, “should”, “will”, “plans”, “believes”,
“estimates”, “targets”, “projects”, “forecasts”, “seeks” and
similar words and expressions. In addition, there can be no
assurance that future developments affecting us will be those that
we anticipate. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to difficulties or delays in development, testing,
regulatory approval, production and marketing of our products
(including the First Defense® product line and
Re-Tain™), competition within our anticipated
product markets, customer acceptance of our new and existing
products, product performance, alignment between our manufacturing
resources and product demand, our reliance upon third parties for
financial support, products and services, changes in laws and
regulations, decision making and delays by regulatory authorities,
currency values and fluctuations and other risks detailed from time
to time in filings we make with the SEC, including our Quarterly
Reports on Form 10-Q, our Annual Reports on Form 10-K and our
Current Reports on Form 8-K. Such statements involve risks and
uncertainties and are based on our current expectations, but actual
results may differ materially due to various factors summarized
above.
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Sep 2023 to Sep 2024